• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA与浆液性卵巢癌发生中的早期事件

BRCA and Early Events in the Development of Serous Ovarian Cancer.

作者信息

George Sophia H L, Shaw Patricia

机构信息

Department of Laboratory Medicine and Pathobiology, Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON , Canada.

出版信息

Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014.

DOI:10.3389/fonc.2014.00005
PMID:24478985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3901362/
Abstract

Women who have an inherited mutation in the BRCA1 or BRCA2 genes have a substantial increased lifetime risk of developing epithelial ovarian cancer (EOC), and epidemiological factors related to parity, ovulation, and hormone regulation have a dramatic effect on the risk in both BRCA mutation carriers and non-carriers. The most common and most aggressive histotype of EOC, high-grade serous carcinoma (HGSC), is also the histotype associated with germline BRCA mutations. In recent years, evidence has emerged indicating that the likely tissue of origin of HGSC is the fallopian tube. We have reviewed, what is known about the fallopian tube in BRCA mutation carriers at both the transcriptional and translational aspect of their biology. We propose that changes of the transcriptome in BRCA heterozygotes reflect an altered response to the ovulatory stresses from the microenvironment, which may include the post-ovulation inflammatory response and altered reproductive hormone physiology.

摘要

携带BRCA1或BRCA2基因遗传突变的女性一生中患上皮性卵巢癌(EOC)的风险大幅增加,与生育、排卵及激素调节相关的流行病学因素对BRCA突变携带者和非携带者的风险均有显著影响。EOC最常见且侵袭性最强的组织学类型,即高级别浆液性癌(HGSC),也是与种系BRCA突变相关的组织学类型。近年来,有证据表明HGSC可能的组织起源是输卵管。我们从生物学的转录和翻译层面综述了关于BRCA突变携带者输卵管的已知情况。我们提出,BRCA杂合子中转录组的变化反映了对来自微环境的排卵应激的反应改变,这可能包括排卵后的炎症反应和生殖激素生理的改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/d1f6f3d8fde3/fonc-04-00005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/9673fc346013/fonc-04-00005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/65c70555bbdf/fonc-04-00005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/d1f6f3d8fde3/fonc-04-00005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/9673fc346013/fonc-04-00005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/65c70555bbdf/fonc-04-00005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894e/3901362/d1f6f3d8fde3/fonc-04-00005-g003.jpg

相似文献

1
BRCA and Early Events in the Development of Serous Ovarian Cancer.BRCA与浆液性卵巢癌发生中的早期事件
Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014.
2
Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.在正常的 FTE 中,增生是卵泡期的一个标志,而不是 BRCA 突变状态。
Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.
3
mutation in high grade epithelial ovarian cancers.高级别上皮性卵巢癌中的突变
Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
4
The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.作为高级别浆液性卵巢癌起源部位的输卵管:范式转变综述
J Obstet Gynaecol Can. 2014 Feb;36(2):133-140. doi: 10.1016/S1701-2163(15)30659-9.
5
Cell Origins of High-Grade Serous Ovarian Cancer.高级别浆液性卵巢癌的细胞起源
Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433.
6
Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.对BRCA1和BRCA2突变携带者进行降低风险的输卵管卵巢切除术所获得的卵巢和输卵管上皮中γ-H2AX和p53核表达水平的定量分析。
Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
7
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.有和没有种系 BRCA 突变的女性输卵管癌的风险因素。
Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.
8
Concurrent RB1 loss and -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.RB1基因缺失与[此处缺失具体基因名称]缺陷同时存在预示着输卵管卵巢高级别浆液性癌患者免疫反应增强及长期生存。
medRxiv. 2023 Nov 10:2023.11.09.23298321. doi: 10.1101/2023.11.09.23298321.
9
A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.BRCA 基因突变携带者输卵管中浆液性癌假定前驱病变的谨慎看法。
Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
10
Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention.卵巢癌:以输卵管作为起源部位及预防机会
Front Oncol. 2016 May 2;6:108. doi: 10.3389/fonc.2016.00108. eCollection 2016.

引用本文的文献

1
The relationship between HYDIN and fallopian tubal cilia loss in patients with epithelial ovarian cancer.上皮性卵巢癌患者中HYDIN与输卵管纤毛丧失之间的关系。
Front Oncol. 2025 Jan 9;14:1495753. doi: 10.3389/fonc.2024.1495753. eCollection 2024.
2
The role of extracellular vesicles in the pathogenesis of gynecological cancer.细胞外囊泡在妇科癌症发病机制中的作用。
Front Oncol. 2024 Sep 26;14:1477610. doi: 10.3389/fonc.2024.1477610. eCollection 2024.
3
Primary Peritoneal Carcinosarcoma in a Breast Cancer Patient Harboring a Germline Pathogenic Variant: Case Report.

本文引用的文献

1
Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.视网膜母细胞瘤通路失调机制决定高级别浆液性卵巢癌的临床结局。
Mod Pathol. 2014 Jul;27(7):991-1001. doi: 10.1038/modpathol.2013.218. Epub 2013 Dec 13.
2
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.BRCA1/2 突变携带者的性激素系统:一项病例对照研究。
Lancet Oncol. 2013 Nov;14(12):1226-32. doi: 10.1016/S1470-2045(13)70448-0. Epub 2013 Oct 17.
3
Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
一名携带种系致病变异的乳腺癌患者发生原发性腹膜癌肉瘤:病例报告
Case Rep Oncol. 2024 Jan 3;17(1):1-9. doi: 10.1159/000534179. eCollection 2024 Jan-Dec.
4
The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.抑癌基因 BRCA1/2、妇科和乳腺肿瘤的癌症易感性和基因组不稳定性。
Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3139-3153. doi: 10.31557/APJCP.2023.24.9.3139.
5
The Histopathological Patterns of Ovarian Neoplasms in Different Age Groups: A Retrospective Study in a Tertiary Care Center.不同年龄组卵巢肿瘤的组织病理学模式:在一家三级医疗中心的回顾性研究。
Cureus. 2022 Dec 29;14(12):e33092. doi: 10.7759/cureus.33092. eCollection 2022 Dec.
6
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!卵巢癌的局部HRD检测?是的,我们可以!
Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.
7
Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers.BRCA2与MAGEC3联合表达可预测晚期卵巢癌的预后。
Cancers (Basel). 2022 Sep 28;14(19):4724. doi: 10.3390/cancers14194724.
8
A Protocol for the Acquisition of Comprehensive Proteomics Data from Single Cases Using Formalin-Fixed Paraffin Embedded Sections.一种使用福尔马林固定石蜡包埋切片从单病例获取综合蛋白质组学数据的方案。
Methods Protoc. 2022 Jul 10;5(4):57. doi: 10.3390/mps5040057.
9
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.将精准医学融入妇科肿瘤的当代管理中。
Curr Oncol Rep. 2022 Jul;24(7):889-904. doi: 10.1007/s11912-021-01163-2. Epub 2022 Mar 26.
10
Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies.妇科癌症、癌症干细胞及可能的靶向治疗
Front Pharmacol. 2022 Feb 16;13:823572. doi: 10.3389/fphar.2022.823572. eCollection 2022.
BRCA1 和 BRCA2 基因突变携带者的自然绝经年龄是否早于其非携带者亲属?来自 Kathleen Cuningham 基金会家族性乳腺癌研究联盟的研究结果。
J Clin Oncol. 2013 Nov 1;31(31):3920-5. doi: 10.1200/JCO.2013.49.3007. Epub 2013 Sep 30.
4
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.BRCA1 与 Nrf2 相互作用以调节抗氧化信号和细胞存活。
J Exp Med. 2013 Jul 29;210(8):1529-44. doi: 10.1084/jem.20121337. Epub 2013 Jul 15.
5
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.激素受体表达与卵巢癌生存:卵巢肿瘤组织分析联盟研究。
Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.
6
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.孕激素在乳腺癌中的信号转导:一种被忽视的激素逐渐成为焦点。
Nat Rev Cancer. 2013 Jun;13(6):385-96. doi: 10.1038/nrc3518.
7
Progesterone/RANKL is a major regulatory axis in the human breast.孕激素/RANKL 是人类乳腺中的主要调节轴。
Sci Transl Med. 2013 Apr 24;5(182):182ra55. doi: 10.1126/scitranslmed.3005654.
8
Senescence and aging: the critical roles of p53.衰老与老化:p53 的关键作用。
Oncogene. 2013 Oct 24;32(43):5129-43. doi: 10.1038/onc.2012.640. Epub 2013 Feb 18.
9
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.BRCA1 和 BRCA2 突变携带者在风险降低的输卵管卵巢切除术前存在未被怀疑的肿瘤的长期随访。
Gynecol Oncol. 2013 May;129(2):364-71. doi: 10.1016/j.ygyno.2013.01.029. Epub 2013 Feb 4.
10
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.